Matrix metalloproteinases are involved in the development of acute coronary syndromes, but they are not reliable clinical markers of the occurrence or the outcome of this syndrome. Many limitations in their assessment account for such failure. Functional genetic polymorphisms, as alternatives to plasma levels, might be an interesting alternative.
